Key Takeaways The U.S. Food and Drug Administration has delayed full approval of Novavax's COVID vaccineThe agency says it needs more data before making a final decisionNovavax says its vaccine is ...

Dr Sara Brenner, the FDA's principal deputy commissioner, has paused the approval process for Novavax's Covid-19 vaccine by ...

Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...

In an unusual move, top Trump FDA official Sara Brenner, MD, MPH, directly intervened in an agency review of Novavax's ...

The Food and Drug Administration had already indicated that it approved the vaccine, but new agency leaders are now requesting more data. Meanwhile, FDA staffers who oversaw expert panel meetings on ...